Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells.
The specificities of monoclonal antibodies against melanoma cells were analyzed using radioimmunoassay, mixed-hemadsorption assay, and quantitative absorption on a variety of malignant and nonmalignant cells. Three of the six hybridoma-secreted antibodies bound to the majority of melanoma cell lines, melanoma tumors, and astrocytoma cell lines as well as to all normal and Epstein-Barr virus-transformed lymphocytes tested. The binding pattern coincides with the presence or absence of the DR antigen on human cells. Conversely, two other antibodies, 19-19 and Nu4B, detected two different antigens common to melanoma and astrocytoma cells only. Cloning of melanoma cells resulted in establishment of DR-positive and DR-negative clones, with the binding of Nu4B antibody retained in all.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology*; D001667:Binding, Competitive; D002460:Cell Line; D002478:Cells, Cultured / Q000276:immunology*; D000939:Epitopes; D006801:Humans; D008545:Melanoma / Q000276:immunology* / Q000648:ultrastructure; D051379:Mice; D008819:Mice, Nude; D011863:Radioimmunoassay; D012756:Sheep; D012878:Skin Neoplasms / Q000276:immunology; D014604:Uveal Neoplasms / Q000276:immunology
D000912:Antibodies, Neoplasm; D000939:Epitopes